Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

The Dow Jones Industrial Average got off to a good start in 2025. These five stocks easily bested the index. The post These ...

We recently compiled a list of the 7 Cheap Quarterly Dividend Stocks to Invest in. In this article, we are going to take a ...

Another key plank of Amgen’s remarkable growth in the 1990s and early 2000s was through mergers and acquisitions. It focused on other innovative biotechnology companies, acquiring Synergen in ...

With a market cap of $153.4 billion, Amgen Inc. (AMGN) is a global leader in biotechnology, focusing on innovative human ...

Results include $1.2 billion of sales from rare disease products, driven by TEPEZZA, KRYSTEXXA, UPLIZNA, and TAVNEOS. Earnings reflect acquisition-related costs related to the Horizon acquisition.

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Amgen’s acquisition will give the company access to Reykjavik, DeCODE’s technology used to sequence human genomes. Amgen plans to develop treatments targeting the defective genes found using ...

Amgen posted strong earnings beat and has an attractive dividend, and technical chart forecasting positive future performance ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic ...